NICE Approves Amgen’s Osteoporosis Drug

iStock_000006963239Medium[1]As reported by the Wall Street Journal, the National Institute of Clinical Excellence (NICE) has recommended that Amgen’s osteoporosis drug Denosumab be made publically available on the NHS.

NICE have recommended that Amgen’s drug me made available to postmenopausal patients as postmenopausal women are at an increased risk of osteoporotic fractures are treated with oral bisphosphonates.

Speaking of the recommendation, Carole Longson, Health Technology Evaluation Centre Director at NICE “Our independent Appraisal Committee felt that there was good quality evidence to show that denosumab is a useful addition to the treatment options available for women who can’t have oral bisphosphonates … We believe that older women at increased risk of osteoporotic fractures who cannot take alendronate, and either risedronate and etidronate, should be considered for this drug alongside the other options available in order to help prevent the misery of breaking a bone.”


Are you looking for your next position in the biotechnology industry? Click here to search our current biotechnology jobs online now.


Posted in: Featured Jobs, News
CK Logo in place of featured image